Influence of \textit{SLCO1B1} and \textit{SLCO2B1} Polymorphisms on Tacrolimus Pharmacokinetics and Clinical Response

Camila Alves\textsuperscript{1}, Claudia R Felipe\textsuperscript{2}, Alvaro M Nishikawa\textsuperscript{1}, Patricia C Salgado\textsuperscript{1}, Cristina Fajardo\textsuperscript{1}, Helio T Silva Jr\textsuperscript{2}, Jose Osmar M Pestana\textsuperscript{2}, Denize Zetchaku\textsuperscript{2}, Glaucio Spinelli\textsuperscript{2}, Nagilla Oliveira\textsuperscript{2}, Mario Hiroyuki Hirata\textsuperscript{1}, Rosario DC Hirata\textsuperscript{1} and Alice C Rodrigues\textsuperscript{3}*

\textsuperscript{1}Faculty of Pharmaceutical Sciences, University of Sao Paulo, Brazil
\textsuperscript{2}Hospital do Rim e Hipertensão, Fundação Oswaldo Ramos, Brazil
\textsuperscript{3}Institute of Biomedical Sciences, Department of Pharmacology, University of Sao Paulo, Brazil

\textbf{Abstract}

\textbf{Background:} Immunosuppressant such as tacrolimus have narrow therapeutic range and are often associated with increased risk of nephrotoxicity in individuals that receive this drug after renal transplantation. Variants in transporters genes have been associated with variability in plasma concentration of tacrolimus and higher risk of adverse effects. Our aim was to investigate the effect of \textit{SLCO1B1} (c.388A>G, c.521T>C) and \textit{SLCO2B1} (c.-717T>C) variants on the efficacy and safety of tacrolimus immunosuppressive therapy in kidney transplant recipients.

\textbf{Methods:} \textit{SLCO1B1} and \textit{SLCO2B1} polymorphisms were detected by TaqMan genotyping and were associated to tacrolimus pharmacokinetics and incidence of acute rejection or diarrhea.

\textbf{Results:} Carriers of the allele \textit{SLCO1B1} c.388G had lower dose adjusted blood concentration (CO/D) of tacrolimus when compared to 388AA carriers, while \textit{SLCO1B1} c.521T>C had no effect. Carriers of CC genotype of \textit{SLCO2B1} c.-717T>C SNP had higher CO/D of tacrolimus when compared to TT carriers. When we consider the effect of the haplotype (c.388A>G and c.521T>C) of \textit{SLCO1B1} on tacrolimus CO/D and incidence of rejection, carriers of \textit{SLCO1B1} *1b haplotype had lower CO/D and lower incidence of rejection when compared to wild type haplotype *1a (p<0.05).

\textbf{Conclusions:} \textit{SLCO1B1} and \textit{SLCO2B1} polymorphisms can contribute for a more safety immunossuppressive treatment in kidney recipients.

\textbf{Keywords:} Polymorphisms; Pharmacokinetics; Renal transplant; SLCO; Tacrolimus

\textbf{Introduction}

In 2009 the number of patients in the waiting list for kidney (34 640), liver (4304), kidney/pancreas (576), heart (305) and lung (161) transplants had grown from 44 to 188\% during the previous 7 years [1]. However, the number of transplants performed on Brazil has grown in the last years. Comparing the total of transplants made in 2001 and 2011, it can be noted an increase of 59\%. From the total of 6839 transplants performed in 2011 the majority was of kidney (4957) followed by liver (1883) [www.abto.org.br].

The biggest challenge faced by organ transplant is rejection. Immunosuppressive therapy has been used successfully to increase patient survival by reducing incidence of graft rejection and/ or drug-related toxicity. Nonetheless, individual response of organ transplant recipients differs among immunosuppressive drugs using standardized dose regime. Among factors claimed to influence individual responses to drug therapy are disease state, kidney and liver functions, hormonal levels, pharmacokinetic drug-to-drug interactions, diet, life style, and genetic variation [2].

Tacrolimus is a critical-dose immunosuppressive drug that acts preventing the activation of T lymphocytes inhibiting their immune response. It has a narrow therapeutic index and significant inter- and intra-individual variability in blood concentrations under a fixed-dose regimen. Studies have shown that high plasma concentrations of tacrolimus are related with adverse effects, such as nephrotoxicity, neurotoxicity, hypertension and diabetogenic effects [3]. Therefore, it is important to monitor tacrolimus levels in order to adjust the dose and to provide the benefit of the immunosuppressive treatment.

Genetic polymorphisms in membrane transporters can cause change in their expression or conformation, leading to different individual responses to drugs, which can affect the efficacy or safety of the therapy [4,5].

Several polymorphisms in genes encoding the solute carriers (SLC) have been described, specifically the organic anion transporting polypeptides (OATPs) OATP1B1 (SLCO1B1) and OATP2B1 (SLCO2B1). OATPs are the main proteins in the hepatic uptake of drugs of bloodstream, so they are important targets for understanding of therapeutic variability [6].

OATP1B1 has been involved in the drug interaction between rifampin (an OATP1B1 inhibitor) and the immunosuppressive mycophenolate mofetil. When these drugs were co-administered, an increase of mycophenolate acid (MPA) in blood occurred [7]. Because MPA seems to be transported by OATPs, some studies have investigated the effect of polymorphisms in \textit{SLCO1B1}, \textit{SLCO2B1} and \textit{SLCO1B3} in the pharmacokinetics of MPA and its glucuronide metabolite [8-10].
Tacrolimus was recently recognized as an inhibitor of phalloidin uptake mediated by OATP1B1 [11]. Nonetheless, no previous study has accessed tacrolimus pharmacokinetics in relation to OATP1B1 gene polymorphisms in Caucasians individuals.

Our aim was to investigate the effect of variants of SLCO1B1 (c.388A>G, c.521T>C) and SLCO2B1 (c.-71T>C) genes on the efficacy and safety of tacrolimus immunosuppressive therapy in kidney transplant recipients.

Polymorphisms of SLCO1B1 and SLCO2B1 genes were detected by TaqMan genotyping and were associated to tacrolimus pharmacokinetics. Carriers of the variant allele SLCO1B1 c.388G (r1b) had lower dose adjusted blood concentration of tacrolimus and had lower incidence of acute rejection when compared to the other haplotypes (*1a, *5 and *15; p<0.05).

Material and Methods
Subjects and study protocol
Data from 129 patients that underwent kidney transplant from Kidney and Hypertension Hospital – UNIFESP, Sao Paulo, SP, were recorded. All the patients were informed about the study protocol and gave informed consent. The study protocol was approved by the Ethics Committee of the institution.

The eligibility criteria were: (1) age higher or equal to 18 years old; (2) Terminal renal disease, first kidney grafts recipient from living or deceased donor; (3) Donor age less than 65 years old; (4) reactive antibody against a panel.

Patients pregnant or breastfeeding; with positive serology to HIV or deceased donor; (2) Terminal renal disease, first kidney grafts recipient from living donor; (3) Donor age less than 65 years old; (4) reactive antibody against a panel.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Subjects (129)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receptors</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>43 ± 16</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>68.1 ± 13.2</td>
</tr>
<tr>
<td>Men</td>
<td>70.5 % (91)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>46.5% (60/128)</td>
</tr>
<tr>
<td>Mulattoes</td>
<td>36.4% (47/128)</td>
</tr>
<tr>
<td>Black</td>
<td>10.8% (14/128)</td>
</tr>
<tr>
<td>Others</td>
<td>5.4% (7/128)</td>
</tr>
<tr>
<td>Co-morbidities</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>13.9% (18)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>50.4% (65)</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>2.3% (3)</td>
</tr>
<tr>
<td>BPAR</td>
<td>27.9% (36)</td>
</tr>
<tr>
<td>Donors</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>44 ± 10</td>
</tr>
<tr>
<td>Living donor</td>
<td>58.7% (74/126)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>55.3% (68/123)</td>
</tr>
<tr>
<td>Mulattoes</td>
<td>34.1% (42/123)</td>
</tr>
<tr>
<td>Black</td>
<td>8.1% (10/123)</td>
</tr>
<tr>
<td>Others</td>
<td>3.2% (4/123)</td>
</tr>
<tr>
<td>Immunosuppression at three-months</td>
<td></td>
</tr>
<tr>
<td>TAC concentration (ng/mL)</td>
<td>5.9 ± 2.7</td>
</tr>
<tr>
<td>MPS dose (g/d)</td>
<td>1.4 ± 0.2</td>
</tr>
<tr>
<td>PRED dose (mg/d)</td>
<td>5.6 ± 3.0</td>
</tr>
</tbody>
</table>

Note: number of individuals in parentheses. TAC: tacrolimus, MPS: mycophenolate sodium, PRED: prednisone, BPAR: biopsy-confirmed acute rejection

Table 1: Biodemographical and clinical data of the kidney transplant recipients.
studied are shown in Table 1. The individuals were 43 ± 16 years old and weighted 68.1 ± 13.2 kg. The group was constituted mainly by men (70.5%), whites (46.5%) and first living related kidney transplant recipients. The incidence of biopsy-confirmed acute rejection (BPAR) was 27.9%.

All the patients of study were submitted to initial treatment (3 months) of immunosuppression with tacrolimus (TAC) in association with MPS and prednisone. None of the patients was converted to another scheme of immunosuppressive during the study. At 3 months of the immunosuppressive therapy TAC, MPS and Prednisone blood concentrations were 5.9 ± 2.7 ng/mL, 1.4 ± 0.2 g/d and 5.6 ± 3.0 mg/d, respectively. Tacrolimus mean dose decreased from the third day (0.188 ± 0.003 mg/kg/day) to the second month (0.074 ± 0.003 mg/kg/day). In the first three months after the transplant of treatment (0.188 ± 0.003 mg/kg/day) to the second month (0.074 ± 0.003 mg/kg/day). In the first three months after the transplant TAC concentration reduced progressively from 10.13 ± 0.5 ng/mL in the third day to 5.9 ± 0.2 ng/mL in the third month. Dose-adjusted TAC concentration reduced progressively from 10.13 ± 0.5 ng/mL in the first three months after the transplant (0.188 ± 0.003 mg/kg/day) to the second month (0.074 ± 0.003 mg/kg/day). In the first three months after the transplant TAC concentration reduced progressively from 10.13 ± 0.5 ng/mL in the third day to 5.9 ± 0.2 ng/mL in the third month. Dose-adjusted concentration increased from the third day (0.82 ± 0.04 ng/mL-1/mg) to the second month (1.69 ± 0.09 ng/mL-1/mg).

**SLCO1B1** and **SLCO2B1** polymorphisms

Genotype and allele frequencies were calculated for this sample population. As expected, genotype frequencies for these variants were in Hardy-Weinberg Equilibrium. The frequencies of the two variants alleles (c.388G and c.521C) for SLCO1B1 was 52% and 14%, respectively. Minor allele frequency (MAF) for SLCO1B1 was 52% and 14%, respectively. The frequencies found for the alleles were *1a (39.0%); *1b (46.5%), *15 (6.3%) and *5 (8.2%).

Relationship of SLCO1B1 and SLCO2B1 polymorphisms and tacrolimus pharmacokinetics: The influence of SLCO1B1 and SLCO2B1 polymorphisms on administered dose and concentrations of tacrolimus were investigated. Equal administered doses (D) and levels of tacrolimus (CO) were observed among the genotypes of SLCO1B1 (data not shown). After adjusting concentration (CO/D) of tacrolimus for dose administered, homozygous carriers for SLCO1B1 c.388G allele presented lower CO/D after 28, 60 and 90 days of therapy compared to AA or AG carriers (Figure 1A). SLCO1B1 c.521C allele had no effect on tacrolimus pharmacokinetic parameters (Figure 1A).

SLCO1B1 polymorphisms are in linkage disequilibrium as observed before, so we have evaluated the effect of the haplotype on acute rejection. SLCO1B1*1b presented lower CO/D after 28, 60 and 90 days of TAC therapy and lower TAC blood levels after 28 days (Figure 1B).
SLCO1B1 
Rejection Genotypes, % (n) Alleles, %
c.388A>G AA AG GG A G
Yes (36) 36.1 (13) 33.3 (12) 30.6 (11) 52.8 47.2
No (92) 22.0 (20) 44.5 (41) 35.2 (30) 45.1 54.9
\( \chi^2 = 2.542, df=2, p=0.281 \) \( \chi^2 = 0.933, 1 df, p=0.334 \)
c.521T>C TT CT CC T C
Yes (36) 72.2 (26) 25.0 (9) 2.8 (1) 84.7 15.3
No (92) 76.1 (70) 20.6 (19) 3.3 (3) 86.4 13.6 \( \chi^2 = 0.152, 2 gl, p=0.935 \)
\( \chi^2 = 0.022, 1 df, p=0.881 \)
SLCO2B1 c.-71T>C TT CT CC T C
Yes (36) 33.3 (12) 44.5 (16) 22.2 (8) 44.4 55.6
No (92) 21.7 (20) 47.8 (44) 30.4 (28) 54.3 45.7 \( \chi^2 = 0.135, 2 gl, p=0.935 \)
\( \chi^2 = 1.65, 1 df, p=0.198 \)
SLCO1B1 haplotype *1a *1b *5 *15
Yes (70) 48.6 (34) 35.7 (25) 4.3 (3) 11.4 (8)
No (180) 34.4 (62) 51.7 (93) 9.5 (17) 4.4 (8)
\( \chi^2 = 10.85, 3 gl, p=0.012 \)

Table 2: Relationship of SLCO1B1 and SLCO2B1 polymorphisms and biopsy-confirmed acute rejection.

Diarrhea Genotypes, % (n) Alleles, %
c.388A>G AA AG GG A G
Yes (35) 31.4 (11) 42.9 (15) 25.7 (9) 52.9 47.1
No (94) 24.5 (23) 39.4 (37) 36.2 (34) 44.1 55.9
\( \chi^2 = 1.383, 2 df, p=0.501 \) \( \chi^2 = 1.224, 1 df, p=0.268 \)
c.521T>C TT CT CC T C
Yes (35) 77.2 (27) 17.1 (6) 5.7 (2) 85.7 14.3
No (94) 73.4 (69) 24.5 (23) 2.1 (2) 85.6 14.4 \( \chi^2 = 1.715, 2 df, p=0.424 \)
\( \chi^2 = 0.034, 1 df, p=0.854 \)
SLCO2B1 2B1-71T>C CC CT TT C T
Yes (35) 20.0 (7) 42.9 (15) 37.1 (13) 41.4 58.6
No (94) 23.4 (22) 48.9 (46) 27.7 (26) 52.1 47.9 \( \chi^2 = 0.069, 2 df, p=0.581 \)
\( \chi^2 = 0.613, 1 df, p=0.434 \)
SLCO1B1 haplotype *1a *1b *5 *15
Yes (68) 47.0 (32) 39.7 (27) 7.3 (5) 6.0 (4)
No (186) 35.5 (66) 50.0 (93) 8.1 (15) 6.4 (12)
\( \chi^2 = 2.904, 3 df, p=0.407 \)

Table 3: Relationship between SLCO1B1 and SLCO2B1 polymorphisms and diarrhea.

For SLCO2B1, a higher CO/D after 28, 60 and 90 days was observed for TC and CC carriers when compared to TT carriers (Figure 1A).

We postulated that SLCO2B1 and SLCO1B1 polymorphisms could be associated contributing both to tacrolimus pharmacokinetics. SLCO2B1 -71T>C was not associated to SLCO1B1 c.388A>G (\( \chi^2 = 7.361, 4 gl, p=0.118 \)), however it was associated to SLCO1B1 c.521T>C SNP (\( \chi^2 = 12.776, 4 gl, p=0.012 \)). As SLCO1B1 are consistently associated, we have also compared SLCO1B1 haplotype and SLCO2B1 SNP frequencies. SLCO1B1*1b homozygous (c.388G and c.521C carriers) were associated to SLCO2B1 -71T allele (p=0.002).

Relationship of SLCO1B1 and SLCO2B1 polymorphisms and acute rejection and adverse effects: BPAR was observed in 36 kidney transplant recipients. Despite the fact that SLCO1B1 or SLCO2B1 polymorphisms affect tacrolimus blood concentrations, there was no difference in the incidence of acute rejection among the genotypes of these polymorphisms (Table 2). However, after we evaluate the effect of the SLCO1B1 haplotype on acute rejection, the distribution of the positive cases for acute rejection were different among the haplotype alleles *1a, *1b, *5 and *15 (\( \chi^2 = 10.85, 3 df, p=0.012 \)) (Table 2).

We have performed a multivariate analysis for variables related to biopsy-confirmed renal graft acute rejection, using SLCO1B1 haplotypes, type of donor (living or deceased donor), tacrolimus blood levels at 28 days after transplant as covariates. Homozygous for SLCO1B1 *1b allele and carrying one SLCO1B1*5 allele were independently predictive for lower incidence of rejection (Odds ratio: *1b/*1b 0.135 [0.0241-0.755], p=0.02; *5 carriers: 0.182 [0.0289-1.147], p=0.07) and living donor was a risk factor for acute rejection (odds ratio: 3.185 [1.186-8.533], p=0.02).

The most frequent adverse effect after tacrolimus/ MPS treatment was diarrhea (27.1%), followed by dyslipidemia (7%) and diabetes mellitus (9.3%). Renal dysfunction considered as creatinine clearance < 40 mL/min was observed in only 7 individuals (5.4%) after 3 months of therapy. Then, we evaluate the relationship between polymorphisms and diarrhea in this sample (Table 3). No differences in the incidence of diarrhea was found in SLCO1B1 c.388G allele or c.521C allele carriers compared with those carrying the wild –type allele (p=0.268). Haplotype analyses, which combined the two alleles (c.388G and c.521C), has also shown no differences in the incidence of diarrhea (p=0.407). SLCO2B1 SNP was also not associated with diarrhea.

Discussion

In this study we have demonstrated that c.388A>G variant of SLCO1B1 is significantly and independently associated with lower CO/D of tacrolimus in kidney transplant recipients at 1, 2 and 3 months post-transplant. Indeed, in our population, this genetically -determined bioavailability of tacrolimus confers a 20% and 40% lower dose-adjusted concentration of tacrolimus for heterozygous (1.80 vs. 2.15 ng.mL-1/mg) and homozygous for c.388G allele (1.26 vs 2.15 ng.mL-1/mg), respectively. These observations are in accordance with in vivo studies, which described that this variant is associated with higher activity of OATP1B1 in subjects carrying c.388G variant (*1b), resulting in lower bioavailability of pravastatin [14] and pitavastatin [15], and tacrolimus [16]. On the other hand, C allele carriers of SLCO2B1 -71T>C SNP were associated with higher CO/D of tacrolimus in kidney transplant recipients after 28, 60 and 90 days after transplant. OATP2B1, OATP1B1 uptake transporter is primarily expressed in the liver, whereas OATP2B1 is widely expressed in tissues including the small intestine, liver, and kidney [17]. The effect of the SLCO2B1 -71T>C variant on OATP2B1 protein is not known, but we may postulate that it could lead to a transporter with impaired uptake activity and this could result in reduced cellular uptake of tacrolimus by kidney. Although, we did not find an association between SLCO2B1 SNP and tacrolimus toxicity and biopsy-proven rejection. We found that individuals carrying *71C allele were also carriers of SLCO1B1 c.521C allele, a SNP that leads to an OATP1B1 transporter with impaired function [18], resulting in reduced uptake of Tac by hepatocytes. Thus, the fact that SLCO2B1 -71C carriers have higher tacrolimus blood levels, could also be attributed to SLCO1B1 c.521C>C SNP. In our sample, only 4 individuals were carriers of CC genotype for SLCO1B1 c.521C>C, which may be too low to observe an effect on tacrolimus pharmacokinetics.

Miura et al. [8] investigated the effect of SLCO1B1, 2B1 and 1B3
on mycophenolic acid (MPA) and tacrolimus pharmacokinetics in Japanese renal transplant recipients. In their study, the pharmacokinetic parameters of MPA or tacrolimus at 28 days post-transplant were not influenced by SLCO1B1, IB3, or 2B1 genetic polymorphisms. However, in another study by the same group, the phenolic MPA glucuronide (MPAG) dose-adjusted AUC0–12 was significantly greater in recipients with SLCO1B1 1a/1a, 1a/1b, or 1b/1b than in those with the *15 allele (P=0.0020) [10]. The effect of SLCO1B1*5 was not investigated, probably because the incidence of c.521C allele on Japanese individuals is very low (0.7%) [19].

The effect of SLCO1B1 and SLCO2B1 polymorphisms on tacrolimus safety was also investigated. Lower frequency of SLCO1B1 *5 allele in the group of individuals who had acute rejection and higher SLCO1B1*1b frequency in the group that had not rejection was observed. Despite the fact this seems to be inconsistent with the low levels of blood tacrolimus concentrations found in c.388G and SLCO1B1*1b carriers, probably there are other mechanisms and other polymorphisms involved in kidney acute rejection. Capron et al. [20] studying liver transplant patients showed that tacrolimus hepatic concentrations varied markedly among patients and were well correlated with the histological rejection score (Banff score), whereas no correlation was found between the Banff score and trough blood concentrations. It was shown that high tacrolimus hepatic concentrations after the first week of surgery appeared to protect against rejection. In this line, SLCO1B1*1b carriers have low levels of tacrolimus on blood, however we do not know tacrolimus kidney concentration, which may be are higher in these variant carriers, protecting them from acute rejection.

Diarrhea was the most frequent adverse effect observed, however its incidence was not associated to SLCO1B1 or SLCO2B1 SNPs. A relationship between high MPA levels and diarrhea in kidney transplant recipients has been reported [21]. A potential limitation of this study is that we did not measure MPA or MPAG plasma concentration, and then we could not associate MPA levels with SLCO polymorphisms. Zucker et al. [22] described higher MPA levels in individuals treated with MMF and tacrolimus when compared to those treated with MMF and cyclosporine. It is feasible to consider that tacrolimus could influence the transportation of MPA or its metabolites mediated by OATP1B1 and it would result in higher MPA/MPAG plasma concentrations. Accordingly, tacrolimus in OATP1B1 in vitro studies was able to inhibit the transport of phalloidin [11]. In addition, Michelon and collaborators [23], using in vitro experiments, showed that MPA metabolites MPA-phenyl-glucuronide and MPA-acetyl-glucuronide are substrates of OATP1B1, and their transport was decreased in the presence of the variant transporter (OATP1B1*5).

In conclusion, carriers of the SLCO1B1 c.388G and SLCO1B1*1b haplotype resulted in a lower dose adjusted concentration of tacrolimus and they had lower incidence of biopsy-proven acute rejection when compared to the other haplotypes (*1a, *5 and *15). These genetic variants may contribute for a safer treatment with tacrolimus, however others polymorphism/genes may be involved in tacrolimus efficacy/safety and should be taken into account. Investigations have been limited to small candidate gene studies in allograft recipients and whole genome analysis studies are required to fulfill the genetic determinants of renal transplant outcome.

Acknowledgment

Alice C. Rodrigues, Patricia C. Salgado were recipients of fellowships from FAPESP, Sao Paulo, Brazil. Camila Alves was a recipient of fellowships from CNPq, Mario H. Hirata and Rosario D.C. Hirata are recipients of fellowships from CNPq, FAPESP, Brazilia, Brazil. This work was supported by grants from FAPESP (2011/10039-6) and CAPES.

References


Submit your next manuscript and get advantages of OMICS Group submissions

**Unique features:**
- User friendly/feasible website-translation of your paper to 50 world’s leading languages
- Audio Version of published paper
- Digital articles to share and explore

**Special features:**
- 350 Open Access Journals
- 30,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: [http://www.omicsonline.org/submission](http://www.omicsonline.org/submission)